Search Results

Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial

Authors: Joshi, Rohina; Galan, BE de; Chalmers, John; Perkovic, Vlado; Patel, Anushka

Source: Expert Review of Endocrinology and Metabolism, Volume 4, Number 2, March 2009 , pp. 111-118(8)

Publisher: Expert Reviews

The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study)

Authors: Barnett; Krentz; Strojek; Sieradzki; Azizi; Embong; Imamoglu; Perušičová; Uličiansky; Winkler

Source: Diabetes, Obesity and Metabolism, Volume 10, Number 12, December 2008 , pp. 1239-1247(9)

Publisher: Blackwell Publishing

Is Ramadan Fasting Safe in Type 2 Diabetic Patients in View of the Lack of Significant Effect of Fasting on Clinical and Biochemical Parameters, Blood Pressure, and Glycemic Control?

Authors: M'guil, M.; Ragala, M. A.; El Guessabi, L.; Fellat, S.; Chraibi, A.; Chebraoui, L.; Israili, Z. H.; Lyoussi, B.

Source: Clinical and Experimental Hypertension, Volume 30, Number 5, July 2008 , pp. 339-357(19)

Publisher: Informa Healthcare

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects

Authors: Zhang, Yifan; Si, Dayong; Chen, Xiaoyan; Lin, Nan; Guo, Yingjie; Zhou, Hui; Zhong, Dafang

Source: British Journal of Clinical Pharmacology, Volume 64, Number 1, July 2007 , pp. 67-74(8)

Publisher: Blackwell Publishing

Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes

Source: Diabetes, Obesity and Metabolism, Volume 9, Number 1, January 2007 , pp. 127-129(3)

Publisher: Blackwell Publishing

Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-α plasma levels in individuals with type 2 diabetes mellitus

Authors: Drzewoski, Jozef; Zurawska-Klis, Monika

Source: Current Medical Research and Opinion, Volume 22, Number 10, October 2006 , pp. 1921-1926(6)

Publisher: Informa Healthcare

Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients

Authors: Lu, C.-H.; Chang, C.-C.; Chuang, L.-M.; Wang, C. Y.; Jiang, Y. D.; Wu, H. P.

Source: Diabetes, Obesity and Metabolism, Volume 8, Number 2, March 2006 , pp. 184-191(8)

Publisher: Blackwell Publishing

The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes)

Author: Kardas, P.

Source: Diabetes, Obesity and Metabolism, Volume 7, Number 6, November 2005 , pp. 722-728(7)

Publisher: Blackwell Publishing

Gliclazide Modified Release

Author: Adis International Limited,

Source: Drugs, Volume 65, Number 10, 2005 , pp. 1449-1450(2)

Publisher: Adis International

Gliclazide modified release : results of a 2-year study in patients with type 2 diabetes

Authors: Drouin, P.; Standl, E.

Source: Diabetes, Obesity and Metabolism, Volume 6, Number 6, November 2004 , pp. 414-421(8)

Publisher: Blackwell Publishing

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

Authors: Schernthaner, G.; Grimaldi, A.; Di Mario, U.; Drzewoski, J.; Kempler, P.; Kvapil, M.; Novials, A.; Rottiers, R.; Rutten, G. E. H. M.; Shaw, K. M.

Source: European Journal of Clinical Investigation, Volume 34, Number 8, August 2004 , pp. 535-542(8)

Publisher: Blackwell Publishing

Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation

Authors: Frey N.; Laveille C.; Paraire M.; Francillard M.; Holford N.H.G.; Jochemsen R.

Source: British Journal of Clinical Pharmacology, Volume 55, Number 2, February 2003 , pp. 147-157(11)

Publisher: Blackwell Publishing

Gliclazide Modified Release

Authors: McGavin J.K.; Perry C.M.; Goa K.L.

Source: Drugs, Volume 62, Number 9, 2002 , pp. 1357-1364(8)

Publisher: Adis International

Gliclazide Modified Release: A Viewpoint by Andrew Harrower

Author: Harrower A.

Source: Drugs, Volume 62, Number 9, 2002 , pp. 1365-1366(2)

Publisher: Adis International

Gliclazide Modified Release: A Viewpoint by Pierre-Jean Guillausseau

Author: Guillausseau P-J.

Source: Drugs, Volume 62, Number 9, 2002 , pp. 1365-1366(2)

Publisher: Adis International

In vitro and in vivo antioxidant properties of gliclazide

Authors: O'Brien R.C.; Luo M.; Balazs N.; Mercuri J.

Source: Journal of Diabetes and its Complications, Volume 14, Number 4, July 2000 , pp. 201-206(6)

Publisher: Elsevier

Comparative Tolerability of Sulphonylureas in Diabetes Mellitus

Author: Harrower A.D.B.

Source: Drug Safety, Volume 22, Number 4, April 2000 , pp. 313-320(8)

Publisher: Adis International